Fisher Asset Management LLC Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Fisher Asset Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 7,398 shares of the medical research company’s stock after purchasing an additional 341 shares during the period. Fisher Asset Management LLC’s holdings in IQVIA were worth $1,753,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. PGGM Investments increased its stake in shares of IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 4,326 shares during the period. Simplify Asset Management Inc. grew its position in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Raymond James & Associates raised its stake in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after buying an additional 5,417 shares during the last quarter. Versor Investments LP purchased a new stake in shares of IQVIA in the third quarter worth about $1,328,000. Finally, Gradient Investments LLC grew its holdings in IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after acquiring an additional 6,134 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.2 %

IQV opened at $200.96 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company’s 50 day simple moving average is $218.67 and its two-hundred day simple moving average is $226.20. The firm has a market capitalization of $36.47 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on IQV shares. Barclays dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Morgan Stanley cut their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.